# Clinical Outcomes Data for Hydroxyurea in CMML

## Structured Data Table

| Efficacy Measure | Value | Citation |
|-----------------|-------|----------|
| Complete Response | 8.9 | PMID: 36455187 |
| Partial Response | 15.7 | PMID: 36455187 |
| Marrow Cr | 12.3 | PMID: 36455187 |
| Progression Free Survival | 6.3 | PMID: 36455187 |
| Overall Survival | 12.1 | PMID: 36455187 |
| Event Free Survival | 10.3 | PMID: 36455187 |
| Grade 3-4 Neutropenia | 18.7% | PMID: 36455187 |
| Grade 3-4 Thrombocytopenia | 11.2% | PMID: 36455187 |
| Febrile Neutropenia | 7.4% | PMID: 36455187 |

## Drug Summary

Hydroxyurea demonstrates a complete response rate of 8.9% and partial response rate of 15.7%. Median overall survival is 12.1 months with progression-free survival of 6.3 months. Based on 1 studies, the most common serious adverse events include Grade 3-4 Neutropenia (18.7%), Grade 3-4 Thrombocytopenia (11.2%), Febrile Neutropenia (7.4%). The drug shows moderate efficacy in CMML with manageable toxicity profile.

## Citations

- **PMID 36455187**: Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia
  - DOI: 10.1200/JCO.22.00437
  - Year: 2023

